These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16049637)

  • 41. Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.
    Ho BL; Kao YH; Chou MC; Yang YH
    J Alzheimers Dis; 2016 Aug; 54(1):351-7. PubMed ID: 27567838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery.
    Mosconi L; Berti V; Quinn C; McHugh P; Petrongolo G; Osorio RS; Connaughty C; Pupi A; Vallabhajosula S; Isaacson RS; de Leon MJ; Swerdlow RH; Brinton RD
    PLoS One; 2017; 12(10):e0185926. PubMed ID: 29016679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
    Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease.
    Ishii K; Sasaki M; Kitagaki H; Yamaji S; Sakamoto S; Matsuda K; Mori E
    J Nucl Med; 1997 Jun; 38(6):925-8. PubMed ID: 9189143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
    Blesa González R; Boada Rovira M; Martínez Parra C; Gil-Saladié D; Almagro CA; Gobartt Vázquez AL;
    Neurologia; 2011 Jun; 26(5):262-71. PubMed ID: 21227548
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years].
    Lipczyńska-Łojkowska W; Ryglewicz D; Jedrzejczak T; Jakubowska T; Kotapka-Minc S; Sienkiewicz-Jarosz H; Bochyńska A
    Neurol Neurochir Pol; 2004; 38(6):471-81. PubMed ID: 15654671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impaired cerebral glucose metabolism in prodromal Alzheimer's disease differs by regional intensity normalization.
    Küntzelmann A; Guenther T; Haberkorn U; Essig M; Giesel F; Henze R; Schroeter ML; Schröder J; Schönknecht P
    Neurosci Lett; 2013 Feb; 534():12-7. PubMed ID: 23182881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Which rivastigmine formula is better for heart in elderly patients with Alzheimer's disease: oral or patch?
    Isik AT; Soysal P; Yay A
    Am J Alzheimers Dis Other Demen; 2014 Dec; 29(8):735-8. PubMed ID: 24867375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive dysfunction in patients with very mild Alzheimer's disease and amnestic mild cognitive impairment showing hemispheric asymmetries of hypometabolism on ¹⁸F-FDG PET.
    Murayama N; Ota K; Kasanuki K; Kondo D; Fujishiro H; Fukase Y; Tagaya H; Sato K; Iseki E
    Int J Geriatr Psychiatry; 2016 Jan; 31(1):41-8. PubMed ID: 25820930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cerebral glucose metabolism in patients with frontotemporal dementia.
    Ishii K; Sakamoto S; Sasaki M; Kitagaki H; Yamaji S; Hashimoto M; Imamura T; Shimomura T; Hirono N; Mori E
    J Nucl Med; 1998 Nov; 39(11):1875-8. PubMed ID: 9829574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
    Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.
    Gauthier S; Juby A; Rehel B; Schecter R
    Int J Clin Pract; 2007 Jun; 61(6):886-95. PubMed ID: 17504350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia.
    Castellano CA; Nugent S; Paquet N; Tremblay S; Bocti C; Lacombe G; Imbeault H; Turcotte É; Fulop T; Cunnane SC
    J Alzheimers Dis; 2015; 43(4):1343-53. PubMed ID: 25147107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease.
    Kadir A; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2006 Nov; 188(4):509-20. PubMed ID: 16832659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.